Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-Inositol using magnetic resonance spectroscopic imaging

Alzheimer Disease and Associated Disorders

Volumn 20, Issue 2, 2006, Pages 77-85

  Zhu, Xiaoping ^a,e   Schuff, Norbert ^a   Kornak, John ^a   Soher, Brian ^d   Yaffe, Kristine ^b   Kramer, Joel H ^b   Ezekiel, Frank ^a   Miller, Bruce L ^a   Jagust, William J ^c   Weiner, Michael W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; Brain myo Inositol; Short TE 1H magnetic resonance spectroscopic imaging

Indexed keywords

BRAIN PROTEIN; INOSITOL; N ACETYLASPARTIC ACID;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FRONTAL CORTEX; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MALE; MEDICAL ASSESSMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; WHITE MATTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASPARTIC ACID; BRAIN MAPPING; CREATINE; FEMALE; FRONTAL LOBE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INOSITOL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARIETAL LOBE; REFERENCE VALUES; STATISTICS;

EID: 33748102973     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000213809.12553.fc     Document Type: Article

References (68)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berlin). 1991;82:239-259.
2. Braak E, Braak H. Alzheimer's disease: transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon's horn. Acta Neuropathol (Berlin). 1997;93:323-325.
3. Lee BC, Mintun M, Buckner RL, et al. Imaging of Alzheimer's disease. J Neuroimaging. 2003;13:199-214.
4. Du AT, Schuff N, Zhu XP, et al. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology. 2003;60:481-486.
5. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41:1920-1928.
6. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 2001;56:592-598.
7. Bates TE, Strangward M, Keelan J, et al. Inhibition of N-acetyl aspartate production: implications for 1H MRS studies in vivo. Neuroreport. 1996;7:1397-1400.
8. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev. 1989;13:23-31.
9. Griffin JL, Bollard M, Nicholson JK, et al. Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed. 2002;15:375-384.
10. Schuff N, Capizzano AA, Du AT, et al. Selective reduction of Nacetyl aspartate in medial temporal and parietal lobes in AD. Neurology. 2002;58:928-935.
11. Hsu YY, Du AT, Schuff N, et al. Magnetic resonance imaging and magnetic resonance spectroscopy in dementias. J Geriatr Psychiatry Neurol. 2001;14:145-166.
12. Ross BD, Bluml S, Cowan R, et al. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am. 1998;8:809-822.
13. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993;15:289-298.
14. Akiyama H, Arai T, Kondo H, et al. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord. 2000;14 (Suppl 1):S47-S53.
15. Meda L, Baron P, Scarlato G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol Aging. 2001;22:885-893.
16. Miller BL, Moats RA, Shonk T, et al. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology. 1993;187:433-437.
17. Moats RA, Ernst T, Shonk TK, et al. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med. 1994;32:110-115.
18. Martinez-Bisbal MC, Arana E, Marti-Bonmati L, et al. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur J Neurol. 2004;11:187-193.
19. Kantarci K, Jack CR Jr, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology. 2000;55:210-217.
20. Kantarci K, Petersen RC, Boeve BF, et al. 1H MR spectroscopy in common dementias. Neurology. 2004;63:1393-1398.
21. Ernst T, Chang L, Melchor R, et al. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology. 1997;203:829-836.
22. Chantal S, Braun CM, Bouchard RW, et al. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res. 2004;1003:26-35.
23. Catani M, Cherubini A, Howard R, et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport. 2001;12:2315-2317.
24. Shonk TK, Moats RA, Gifford P, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology. 1995;195:65-72.
25. Parnetti L, Tarducci R, Presciutti O, et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev. 1997;97:9-14.
26. Rose SE, de Zubicaray GI, Wang D, et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging. 1999;17:291-299.
27. Soher BJ, Vermathen P, Schuff N, et al. Short TE in vivo (1)H MR spectroscopic imaging at 1.5 T: acquisition and automated spectral analysis. Magn Reson Imaging. 2000;18:1159-1165.
28. Posse S, DeCarli C, Le Bihan D. Three-dimensional echo-planar MR spectroscopic imaging at short echo times in the human brain. Radiology. 1994;192:733-738.
29. Kapeller P, McLean MA, Griffin CM, et al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol. 2001;248:131-138.
30. Mueller SG, Laxer KD, Suhy J, et al. Spectroscopic metabolic abnormalities in mTLE with and without MRI evidence for mesial temporal sclerosis using hippocampal short-TE MRSI. Epilepsia. 2003;44:977-980.
31. Simister RJ, Woermann FG, McLean MA, et al. A short-echo-time proton magnetic resonance spectroscopic imaging study of temporal lobe epilepsy. Epilepsia. 2002;43:1021-1031.
32. Durazzo TC, Gazdzinski S, Banys P, et al. Cigarette smoking exacerbates chronic alcohol-induced brain damage: a preliminary metabolite imaging study. Alcohol Clin Exp Res. 2004;28:1849-1860.
33. Auer DP, Schirmer T, Heidenreich JO, et al. Altered white and gray matter metabolism in CADASIL: a proton MR spectroscopy and 1H-MRSI study. Neurology. 2001;56:635-642.
34. Block W, Traber F, Kuhl CK, et al. 1H-MR spectroscopic imaging in patients with clinically diagnosed Alzheimer's disease. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1995;163:230-237.
35. Colla M, Ende G, Bohrer M, et al. MR spectroscopy in Alzheimer's disease: gender differences in probabilistic learning capacity. Neurobiol Aging. 2003;24:545-552.
36. Mielke R, Schopphoff HH, Kugel H, et al. Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer's disease. Int J Neurosci. 2001;107:233-245.
37. Tedeschi G, Bertolino A, Lundbom N, et al. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology. 1996;47:696-704.
38. Chao LL, Schuff N, Kramer JH, et al. Reduced medial temporal lobe N-acetyl aspartate in cognitively impaired but nondemented patients. Neurology. 2005;64:282-289.
39. Zhu XP, Young K, Ebel A, et al. Robust analysis of short echo time 1H MRSI of human brain. Magn Reson Med. 2006;55:706-711.
40. Zhu XP, Young K, Soher JB, et al. New spectral analysis of short echotime multislice 1H MRSI in human brain using eigen spectra, baseline correction and frequency alignment. In: Proceedings of the 13th Annual Meeting of ISMRM, Miami Beach, USA, 2005:55.
41. Mungas D, Reed BR, Ellis WG, et al. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol. 2001;58:1243-1247.
42. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
43. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
44. Wiedermann D, Schuff N, Matson GB, et al. Short echo time multislice proton magnetic resonance spectroscopic imaging in human brain: metabolite distributions and reliability. Magn Reson Imaging. 2001;19:1073-1080.
45. Haupt CI, Schuff N, Weiner MW, et al. Removal of lipid artifacts in 1H spectroscopic imaging by data extrapolation. Magn Reson Med. 1996;35:678-687.
46. Soher BJ, Young K, Govindaraju V, et al. Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med. 1998;40:822-831.
47. MacKay S, Ezekiel F, Di Sclafani V, et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology. 1996;198:537-545.
48. Jack CR Jr, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology. 1998;51:993-999.
49. Andreasen NC, Rajarethinam R, Cizadlo T, et al. Automatic atlasbased volume estimation of human brain regions from MR images. J Comput Assist Tomogr. 1996;20:98-106.
50. Pinheiro JC, Bates DM. Mixed-effects Models in S and S-PLUS. New York: Springer; 2000.
51. Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage. 2003;18:525-541.
52. Kantarci K, Jack CR Jr. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am. 2003;13:197-209.
53. Schuff N, Capizzano AA, Du AT, et al. Different patterns of N-acetyl aspartate loss in subcortical ischemic vascular dementia and AD. Neurology. 2003;61:358-364.
54. Choi CG, Frahm J. Localized proton MRS of the human hippocampus: metabolite concentrations and relaxation times. Magn Reson Med. 1999;41:204-207.
55. Waldman AD, Rai GS, McConnell JR, et al. Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr. 2002;35:137-142.
56. Heun R, Schlegel S, Graf-Morgenstern M, et al. Proton magnetic resonance spectroscopy in dementia of Alzheimer type. Int J Geriatr Psychiatry. 1997;12:349-358.
57. Stoppe G, Bruhn H, Pouwels PJ, et al. Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy. Alzheimer Dis Assoc Disord. 2000;14:112-119.
58. Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr. 1987;6:193-208.
59. Neary D, Snowden JS, Northen B, et al. Dementia of frontal lobe type. J Neurol Neurosurg Psychiatry. 1988;51:353-361.
60. Lien YH, Shapiro JI, Chan L. Effects of hypernatremia on organic brain osmoles. J Clin Invest. 1990;85:1427-1435.
61. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58:65-70.
62. Vermathen P, Laxer KD, Matson GB, et al. Hippocampal structures: anteroposterior N-acetyl aspartate differences in patients with epilepsy and control subjects as shown with proton MR spectroscopic imaging. Radiology. 2000;214:403-410.
63. Li BS, Babb JS, Soher BJ, et al. Reproducibility of 3D proton spectroscopy in the human brain. Magn Reson Med. 2002;47:439-446.
64. Klunk WE, Xu C, Panchalingam K, et al. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol Aging. 1996;17:349-357.
65. Fernandez A, Garcia-Segura JM, Ortiz T, et al. Proton magnetic resonance spectroscopy and magnetoencephalographic estimation of delta dipole density: a combination of techniques that may contribute to the diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20:169-177.
66. Dixon RM, Bradley KM, Budge MM, et al. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain. 2002;125:2332-2341.
67. Kantarci K, Xu Y, Shiung MM, et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14:198-207.
68. Antuono PG, Jones JL, Wang Y, et al. Decreased glutamate+glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5T. Neurology. 2001;56:737-742.